xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

434

KUANetal.

escalation and expansion results of a phase IB study. Eur JCancer . 2013;49(2):S856-S857. https://doi.org/10.1016/S0959 8049%2813%2970065-0 1531. Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol . 2017;28(10):2581-2587. https://doi. org/10.1093/annonc/mdx339 1532. Ozturk Sari S, Yilmaz I, Taskin OC, et al. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases. Pathology . 2017;49(1):55-61. https://doi.org/10.1016/j.pathol.2016.09.065 1533. Phlippen M, Prera N, Ludwig-Peitsch W, et al. Melanoma of the nasal cavity - an interdisciplinary challenge. Laryngorhi nootologie . 2021;100(Suppl. 2):S117. https://doi.org/10.1055/s 0041-1727947 1534. Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbe C. Atypical BRAF and NRAS mutations in mucosal melanoma. Cancers . 2019;11(8):1133. https://doi.org/10.3390/ cancers11081133 1535. Garcia-Alvarez A, Ortiz C, Munoz-Couselo E. Current per spectives and novel strategies of NRAS-mutant melanoma. Onco Targets Ther . 2021;14:3709-3719. https://doi.org/10.2147/ OTT.S278095 1536. Munoz-Couselo E, Adelantado EZ, Ortiz C, Garcia JS, Perez Garcia J. NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther . 2017;10:3941-3947. https:// doi.org/10.2147/OTT.S117121 1537. Delyon J, Lebbe C, Dumaz N. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. Curr Opin Oncol . 2020;32(2):79-84. https://doi. org/10.1097/CCO.0000000000000606 1538. Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol . 2017;18(4):435-445. https://doi.org/ 10.1016/S1470-2045(17)30180-8 1539. Lebbe C, Dutriaux C, Lesimple T, et al. Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: phase II, randomized, controlled trial with crossover. Cancers . 2020;12(7):1727. https://doi.org/10. 3390/cancers12071727 1540. Amaral T, Meraz-Torres F, Garbe C. Immunotherapy in man aging metastatic melanoma: which treatment when? Expert Opin Biol Ther . 2017;17(12):1523-1538. https://doi.org/10.1080/ 14712598.2017.1378640 1541. Dabelic N, Brozic JM, Frobe A. Recent advances in targeted therapies of melanoma. Libri Oncologici . 2020;48(Suppl. 1):45 47. 1542. Ling DC, Bakkenist CJ, Ferris RL, Clump DA. Role of immunotherapy in head and neck cancer. Semin Radiat Oncol . 2018;28(1):12-16. https://doi.org/10.1016/j.semradonc.2017.08. 009 1543. Kaunitz GJ, Cottrell TR, Lilo M, et al. Melanoma sub types demonstrate distinct PD-L1 expression profiles. Lab Invest . 2017;97(9):1063-1071. https://doi.org/10.1038/labinvest. 2017.64 1544. Specenier P. Ipilimumab in melanoma. Expert Rev Anticancer Ther . 2016;16(8):811-826. https://doi.org/10.1080/14737140. 2016.1211936

1517. Studentova H, Kalabova H, Koranda P, et al. Immunother apy in mucosal melanoma: a case report and review of the literature. Oncotarget . 2018;9(25):17971-17977. https://doi.org/ 10.18632/oncotarget.24727 1518. Chao TN, Kuan EC, Tong CCL, et al. Surgical treat ment of sinonasal mucosal melanoma in patients treated with systemic immunotherapy. J Neurol Surg B Skull Base . 2021;82(Suppl. 3):e148-e154. https://doi.org/10.1055/s-0040 1701219 1519. Amit M, Tam S, Takahashi Y, Bell D, Roberts D, Hanna E. Mutation status in sinonasal mucosal melanoma. J Neurol Surg B Skull Base . 2017;78(Suppl. 1):S1-S156. https://doi.org/10. 1055/s-0037-1600615 1520. Amit M, Tam S, Abdelmeguid AS, et al. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. BrJCancer . 2017;116(12):1564-1571. https:// doi.org/10.1038/bjc.2017.125 1521. Edwards J, Ferguson PM, Lo SN, et al. Tumor muta tion burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas. Cancer Immunol Res . 2020;8(11):1346-1353. https://doi.org/10.1158/2326-6066. CIR-19-0835 1522. Al-Faraidy N, Deodhare N, Naert K, et al. Molecular pro filing of common melanoma mutations—a large cohort study. Lab Invest . 2015;95:510A-511A. https://doi.org/10.1038/ labinvest.2015.25 1523. Blokx WAM. Molecular diagnostics in melanoma. J Pathol . 2013;229(1):S5. https://doi.org/10.1002/path.4190 1524. Ferrucci PF, Battaglia A, Cocorocchio E, et al. B-Raf, C-Kit and MGMT molecular evaluation on 316 consecutive patients (pts) affected by Metastatic Melanoma (MM) and receiving different treatment combinations - do mutations influence outcome? Eur J Cancer . 2012;48(5):S208. https://doi.org/10. 1016/S0959-8049%2812%2971496-X 1525. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches suc ceed and other fail. Biochem Pharmacol . 2010;80(5):624-637. https://doi.org/10.1016/j.bcp.2010.04.029 1526. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEngl JMed . 2011;364(26):2507-2516. https://doi.org/10.1056/ NEJMoa1103782 1527. Dummer R, Goldinger S, Turtschi C, Gisler S, Eggmann N, Rinderknecht J. Inhibition of the MEK-kinase pathway in advanced melanoma. Onkologie . 2011;34(6):2-3. https://doi. org/10.1159/000333299 1528. Gummadi T, Dronca RS, Kim C, et al. Impact of BRAF mutation and effectiveness of BRAF inhibitor on the brain metastases in patients with metastatic melanoma. J Clin Oncol Conf . 2013;31(15 Suppl. 1):Abstract 9048. 1529. Kim HS, Jang KW, Jung M, Kim SH, Kim TM, Cho BC. Oncogenic BRAF fusion induces MAPK-pathway activation targeted by MEK inhibitor and phosphatidylinositol 3-kinase inhibitor combination treatment in mucosal melanoma. Can cerRes . 2015;75(15 Suppl. 1):3942. https://doi.org/10.1158/1538 7445.AM2015-3942 1530. McArthur G, Gonzalez R, Pavlick A, et al. Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC-0973), in advanced BRAFV600-mutated melanoma (BRIM7): dose